Search research articles
Contact Us
Filters
Showing results (1-10 of 160) with videos related to
Page
of 16
Sort By:
Anti-Cancer Drug Design
|
July 11, 2000
Protein kinase antagonists: interim challenges and issues
E A Sausville
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
August 8, 2001
Scientific summation and future goals
E A Sausville
Cancer Research
|
January 4, 1998
Correspondence re: G. Palumbo et al., the tyrphostin AG17 induces apoptosis and inhibition of cdk2 activity in a lymphoma cell line that overexpresses bcl-2. Cancer Res., 57: 2434-2439, 1997
E A Sausville
Cancer Journal (Sudbury, Mass.)
|
July 6, 2000
Use of immunotoxins in the treatment of lymphoma
E A Sausville
Journal of the National Cancer Institute
|
October 19, 2000
Dragons 'round the fleece again: STI571 versus alpha1 acid glycoprotein
E A Sausville
Journal of Chemotherapy (Florence, Italy)
|
February 4, 2005
Target selection issues in drug discovery and development
E A Sausville
Journal of the National Cancer Institute
|
January 29, 1999
A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges
E A Sausville
Current Opinion in Investigational Drugs (London, England : 2000)
|
March 16, 2001
Overview. Cancer drug discovery: pathway promise or covalent certainty for drug effect--quo vadis?
E A Sausville
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2001
Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Commentary re: P. Münster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res., 7: 2228-2236, 2001
E A Sausville
Cancer Metastasis Reviews
|
February 8, 2002
The challenge of pathway and environment-mediated drug resistance
E A Sausville
Page
of 16
Search research articles
Search
Showing results (1-10 of 160) with videos related to
Sort By:
Page
of 16
Anti-Cancer Drug Design
|
July 11, 2000
Protein kinase antagonists: interim challenges and issues
E A Sausville
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
August 8, 2001
Scientific summation and future goals
E A Sausville
Cancer Research
|
January 4, 1998
Correspondence re: G. Palumbo et al., the tyrphostin AG17 induces apoptosis and inhibition of cdk2 activity in a lymphoma cell line that overexpresses bcl-2. Cancer Res., 57: 2434-2439, 1997
E A Sausville
Cancer Journal (Sudbury, Mass.)
|
July 6, 2000
Use of immunotoxins in the treatment of lymphoma
E A Sausville
Journal of the National Cancer Institute
|
October 19, 2000
Dragons 'round the fleece again: STI571 versus alpha1 acid glycoprotein
E A Sausville
Journal of Chemotherapy (Florence, Italy)
|
February 4, 2005
Target selection issues in drug discovery and development
E A Sausville
Journal of the National Cancer Institute
|
January 29, 1999
A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges
E A Sausville
Current Opinion in Investigational Drugs (London, England : 2000)
|
March 16, 2001
Overview. Cancer drug discovery: pathway promise or covalent certainty for drug effect--quo vadis?
E A Sausville
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2001
Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Commentary re: P. Münster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res., 7: 2228-2236, 2001
E A Sausville
Cancer Metastasis Reviews
|
February 8, 2002
The challenge of pathway and environment-mediated drug resistance
E A Sausville
Page
of 16